| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-922 | |
| Phytochemical name or plant extracts | Valeric acid | |
| PMID | 33510252 | |
| Literature evidence | This study highlights a potential utility of valeric acid as a novel HDAC inhibitor and a therapeutic agent in the treatment of breast cancer. | |
| IUPAC name | pentanoic acid | |
| Phytochemicals’ class or type of plant extracts | Carboxylic acid | |
| Source of phytochemicals or plant Extracts | Valeriana officinalis | |
| Geographical availability | Albania, Austria, Baltic States, Belarus, Bulgaria, Central European Rus, Czechoslovakia, Denmark, East European Russia, Finland, France, Germany, Hungary, Iran, Italy, Krym, North Caucasus, North European Russi, Northwest European R, Poland, Romania, South European Russi, Sweden, Switzerland, Transcaucasus, Turkey, Turkey-in-Europe, Ukraine, Yugoslavia | |
| Plant parts | Rhizome | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | HDAC | |
| Target pathways | This study highlights a potential utility of valeric acid as a novel HDAC inhibitor and a therapeutic agent in the treatment of breast cancer. | |
| IC50 | NA | |
| Potency | This study highlights a potential utility of valeric acid as a novel HDAC inhibitor and a therapeutic agent in the treatment of breast cancer. | |
| Cell line/ mice model | MCF-7, MDA-MB-231, MCF-10A | |
| Additional information | We then tested anti-proliferative activity of valeric acid at different concentrations against breast cancer cell lines MCF-7, MDA-MB-231 and normal breast epithelial cells MCF-10A at 48 h. Results showed that valeric acid (1 mM, 2.5 mM, 5 mM, and 10 mM) inhibited MCF-7 cells by 27.92 ± 1.05% (p = 0.009), 13.36 ± 0.60% (p = 0.037), 25.15 ± 1.83% (p = 0.006), 50.67 ± 2.57% (p = 0.001), and inhibited MDA-MB-231 cells by 17.07 ± 1.11% (p < 0.001), 26.99 ± 1.21% (p < 0.001), 37.65 ± 1.35% (p < 0.001), 54.44 ± 0.85% (p < 0.001) at 48 h, respectively (Fig. 1C). Valeric acid at 5 mM was further tested for anticancer effect at different time points. Specifically, the proliferation of MCF-7 cells was inhibited by 34.48 ± 3.64% (p = 0.007), 51.95 ± 2.04% (p < 0.001), and 60.02 ± 0.53% (p < 0.001) at 24 h, 48 h, 72 h, respectively, versus 24.13 ± 0.76% (p = 0.003), 37.65 ± 0.35% (p < 0.001), and 42.16 ± 1.91% (p = 0.001) for MDA-MB-231 | |
| PubChem ID | 7991 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:860012-1 | |
| Safety | NA |